Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours

Journal of Pathology

Volumn 211, Issue 3, 2007, Pages 286-295

  Khalique, L ^a   Ayhan, A ^b,c   Weale, M E ^a,d   Jacobs, I J ^a   Ramus, S J ^a   Gayther, S A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HACETTEPE UNIVERSITY   (Turkey)

^c Seirei Mikatahara Hospital   (Japan)

^d DUKE UNIVERSITY   (United States)

Author keywords

Genetic analysis; Intra tumour heterogeneity; Microarray technologies; Ovarian cancer; Parsimonious evolutionary tree analysis

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL KINASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL POPULATION; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARIECTOMY; OVARY CANCER; PARSIMONY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA, PAPILLARY; ALLELES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; GENOTYPE; HUMANS; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33846591472     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2112     Document Type: Article

References (61)

1. Heppner GH. Tumor heterogeneity. Cancer Res 1984;44:2259-2265.
2. Mora J, Cheung NK, Gerald WL. Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer 2001;85:182-189.
3. Van der Poel HG, Oosterhof GO, Schaafsma HE, Debruyne FM, Schalken JA. Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology 1997;49:652-657.
4. Owonikoko T, Rees M, Gabbert HE, Sarbia M. Intratumoral genetic heterogeneity in Barrett adenocarcinoma. Am J Clin Pathol 2002;117:558-566.
5. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Hutzler P, et al. Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet Cytogenet 1999;110:94-102.
6. Losi L, Baisse B, Bouzourene H, Benhattar J. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005;26:916-922.
7. Takata M, Morita R, Takehara K. Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis. Int J Cancer 2000;85:492-497.
8. Ruiz-Cerda JL, Hernandez M, Sempere A, O'Connor JE, Kimler BF, Jimenez-Cruz F. Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognostic significance. Cancer 1999;86:664-671.
9. Struikmans H, Rutgers DH, Hordijk GJ, van der Tweel I, Bartermann JJ. Regional heterogeneity and intra-observer variability of DNA-content and cell proliferation markers determined by flow cytometry in head and neck tumours. Oral Oncol 1999;35:217-223.
10. Furuya T, Uchiyama T, Murakami T, Adachi A, Kawauchi S, Oga A, et al. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer Res 2000;6:2815-2820.
11. Lyng H, Beigi M, Svendsrud DH, Brustugun OT, Stokke T, Kristensen GB, et al. Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix. Int J Cancer 2004;111:358-366.
12. Hessman O, Skogseid B, Westin G, Akerstrom G. Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab 2001;86:1355-1361.
13. Saeki R, Nagai H, Kaneko S, Unoura M, Yamanaka N, Okamoto E, et al. Intratumoral genomic hetetogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning. J Hepatol 2000;33:99-105.
14. Hansen LL, Jensen LL, Dimitrakakis C, Michalas S, Gilbert F, Barber HR, et al. Allelic imbalance in selected chromosomal regions in ovarian cancer. Cancer Genet Cytogenet 2002;139:1-8.
15. Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D, et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 2002;62:3466-3476.
16. Ramus SJ, Pharoah PD, Harrington P, Pye C, Werness B, Bobrow L, et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 2003;63:417-423.
17. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, et al. Serniautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996;56:3331-3337.
18. Felsenstein J. 2004. PHYLIP (Phylogeny Inference Package) version 3.6. Distributed by the author. Department of Genome Sciences, University of Washington, Seattle, USA.
19. Page RD. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996;12:357-358.
20. Abeln EC, Kuipers-Dijkshoorn NJ, Berns EM, Henzen-Logmans SC, Fleuren GJ, Cornelisse CJ. Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence. Br J Cancer 1995;72:1330-1336.
21. Brinkmann D, Ryan A, Ayhan A, McCluggage WG, Feakins R, Santibanez-Koref MF, et al. A molecular genetic and statistical approach for the diagnosis of dual-site cancers. J Natl Cancer Inst 2004;96:1441-1446.
22. Zborovskaya I, Gasparian A, Karseladze A, Elcheva I. Trofimova E, Driouch K, et al. Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity. Int J Cancer 1999;82:822-826.
23. Tavassoli M, Ruhrberg C, Beaumont V, Reynolds K, Kirkham N, Collins WP, et al. Whole chromosome 17 loss in ovarian cancer. Genes Chromosomes Cancer 1993;8:195-198.
24. Launonen V, Mannermaa A, Stenback F, Kosma VM, Puistola U, Huusko P, et al. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet 2000;122:49-54.
25. Israeli O, Goldring-Aviram A, Rienstein S, Ben-Baruch G, Korach J, Goldman B, et al. In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet 2005;160:35-42.
26. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004;90:686-692.
27. Benetkiewicz M, Wang Y, Schaner M, Wang P, Mantripragada KK, Buckley PG, et al. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas. Genes Chromosomes Cancer 2005;42:228-237.
28. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-3696.
29. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;65:10602-10612.
30. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004;23:8065-8077.
31. Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001;159:1231-1238.
32. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005;11:2149-2155.
33. Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR Jr, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004;165:397-414.
34. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-3876.
35. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC, et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 2000;60:6744-6749.
36. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11:6300-6310.
37. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:53-59.
38. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000.
39. Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004;11:51-59.
40. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004;10:3291-3300.
41. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-6126.
42. Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao J, Chang DD. Gene expression in epithelial ovarian carcinoma. Oncogene 2002;21:6289-6298.
43. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007-5011.
44. Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, et al. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005;24:4672-4687.
45. Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 2002;62:2923-2928.
46. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376-4386.
47. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375-385.
48. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 2001;61:5895-5904.
49. Shridhar V, Sen A, Chien J, Staub J, Avula R, Kovats S, et al. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res 2002;62:262-270.
50. Sieben NL, Oosting J, Flanagan AM, Prat J, Roemen GM, Kolkman-Uljee SM, et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 2005;23:7257-7264.
51. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388-7393.
52. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 2001;128:1-6.
53. Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, et al. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 2004;155:97-107.
54. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, et al. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 2005;11:113-122.
55. Warrenfeltz S, Pavlik S, Datta. S, Kraemer ET, Benigno B, McDonald JF. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential. Mol Cancer 2004;3:27.
56. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001;98:1176-1181.
57. Zhang X, Feng J, Cheng Y, Yao Y, Ye X, Fu T, et al. Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays. Int J Gynecol Cancer 2005;15:50-57.
58. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-6430.
59. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-6062.
60. Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H, et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene 2006;25:5581-5590.
61. Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D, et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 2002;62:3466-3476.